Cosmos Health Inc. Announces Closing of $5.25 Million Registered Direct Offering and Concurrent Private Placement
CHICAGO, IL / ACCESSWIRE / July 21, 2023 / Cosmos Health Inc. (the "Company") (Nasdaq:COSM), a global healthcare group with...
Day: July 21, 2023
Allied OMS Announces Appointment of Dr. Jonathon Jundt as Chief Medical Officer
SOUTHLAKE, TX / ACCESSWIRE / July 21, 2023 / Allied OMS - the country's only doctor-owned, doctor-led, and doctor-governed management...
Best’s Special Report: Unprofitable Auto, Property Insurance Results Weaken Property/Casualty Industry’s 2022 Underwriting Performance
OLDWICK, N.J.--(BUSINESS WIRE)--#insurance--Significant deterioration in the U.S. personal lines segment’s underwriting results, particularly in the private passenger auto line of...
Biotricity Regains Nasdaq Listing Compliance
REDWOOD CITY, CA / ACCESSWIRE / July 21, 2023 / Biotricity, Inc. (NASDAQ:BTCY), a Technology-as-a-Service (TaaS) company operating in the...
BioRestorative Therapies (NASDAQ:BRTX) Receives Landmark License From New York State
MELVILLE, NY / ACCESSWIRE / July 21, 2023 / BioRestorative Therapies Inc. (NASDAQ:BRTX) ("BioRestorative"), a clinical-stage company specializing in stem...
Correction: Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
Positive opinion from Committee for Medicinal Products for Human Use (CHMP) based on Bylvay Phase III ASSERT clinical-trial data in...
Janssen Receives Positive CHMP Opinions for Novel Bispecific Antibodies TALVEY®▼ (talquetamab) and TECVAYLI®▼ (teclistamab) for the Treatment of Patients with Relapsed and Refractory Multiple Myeloma
Talquetamab is the first therapy targeting GPRC5D to receive a positive CHMP Opinion Teclistamab, the first BCMA-targeting bispecific antibody to...
Fresh Tracks Announces $8.25 Million Buyout of Its Right to Receive Future Sofpironium Bromide Payments from Botanix
Strengthens cash position as Company continues to evaluate strategic options to maximize shareholder valueBOULDER, Colo., July 21, 2023 (GLOBE NEWSWIRE)...
Genetic Technologies Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
MELBOURNE, Australia, July 21, 2023 (GLOBE NEWSWIRE) -- Genetic Technologies Limited (NASDAQ: GENE, “Company”) a global leader in genomics-based tests...
Ipsen provides update on E.U. Marketing Authorization Application for Bylvay® for cholestatic pruritus in patients with Alagille syndrome
Positive opinion from Committee for Medicinal Products for Human Use (CHMP) based on Bylvay Phase III ASSERT clinical-trial data in...
Renalytix Announces Middle East Distribution Agreement with Vector Pharma
Commercial availability of kidneyintelX.dkd™ expanded to an estimated 4 million DKD Patients in the Middle East Distribution agreement opens kidneyintelX.dkd testing...
Theratechnologies Announces the Resignation of One of Its Directors, Mr. Gary Littlejohn
MONTREAL, July 21, 2023 (GLOBE NEWSWIRE) -- Theratechnologies Inc. (“Theratechnologies” or the “Company”) (TSX: TH) (NASDAQ: THTX), a biopharmaceutical company...
Bluejay Diagnostics Announces Reverse Stock Split
ACTON, Mass., July 21, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology...
RadNet, Inc. Announces Date of its Second Quarter 2023 Financial Results Conference Call
LOS ANGELES, July 21, 2023 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic...
Genmab Announces AbbVie Receives Positive CHMP Opinion for Epcoritamab (TEPKINLY®) for the Treatment of Adults with Relapsed/Refractory (R/R) Diffuse Large B-cell Lymphoma (DLBCL)
Company Announcement The positive CHMP opinion is supported by results from the EPCORE™ NHL-1 phase 1/2 trial evaluating the preliminary...
Triastek Reports Positive FIH Results from Study of T21, a 3D Printed Oral Treatment for Moderate to Severe Ulcerative Colitis
The study verified the ability for Triastek's 3D Microstructure for Colon Targeting (3DμS-CT) to precisely target and release medication in...
Curium Announces Publication of [18F]DCFPyL Versus [18F]Fluoromethylcholine Results From European Phase III Study (PYTHON Trial)
PARIS, July 21, 2023 (GLOBE NEWSWIRE) -- Curium, a world leader in nuclear medicine, announced today the publication of the...
Molecure completes successful Secondary Public Offering (SPO) of approximately PLN 50 million (USD 12 million) with proceeds to be used to fund and build a first in class, sustainable pipeline of breakthrough therapies
Press release Molecure completes successful Secondary Public Offering (SPO) of approximately PLN 50 million (USD 12 million) with proceeds to...
Turnstone Biologics Corp. Announces Pricing of Upsized Initial Public Offering
SAN DIEGO, July 20, 2023 (GLOBE NEWSWIRE) -- Turnstone Biologics Corp. (“Turnstone” or the “Company”) (Nasdaq: TSBX), a clinical-stage biotechnology...
Idorsia announces a cost reduction initiative to be implemented by the end of 2023
Ad hoc announcement pursuant to Art. 53 LR In order to give Idorsia the necessary time to realize commercial success...